Pamela A. Godoy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pamela A. Godoy has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Oscar Ramírez-Molina
Department of Physiology, Faculty of Biological Sciences, Universidad de Concepcion, Concepción 4070386, Chile
2 shared publications - Ana M. Marileo
Department of Physiology, Faculty of Biological Sciences, Universidad de Concepcion, Concepción 4070386, Chile
1 shared publication - Bernardita A. Salgado-Martínez
Department of Physiology, Faculty of Biological Sciences, Universidad de Concepcion, Concepción 4070386, Chile
1 shared publication - Camila Millar-Obreque
Department of Physiology, Faculty of Biological Sciences, Universidad de Concepcion, Concepción 4070386, Chile
1 shared publication - Carlos Felipe Burgos
Department of Physiology, Faculty of Biological Sciences, Universidad de Concepcion, Concepción 4070386, Chile
1 shared publication - Gonzalo E. Yévenes
Departamento de Fisiología, Facultad de Ciencias Biológicas, Universidad de Concepción
1 shared publication
Latest Publications
- Open Access
In Silico Characterization of Gelsemium Compounds as Glycine Receptor Ligands
Glycine receptors (GlyRs) are essential for inhibitory neurotransmission in the central nervous system (CNS) and represent promising targets against neurological disorders. Several indole alkaloids from Gelsemium species have been shown to modulate GlyRs. Notably, the anxiolytic and analgesic properties of certain Gelsemium alkaloids appear to depend on GlyR modulation. However, prior studies have focused on only a few indole alkaloids, leaving the activity of other Gelsemium compound classes unexplored. This study employed an integrative in silico approach to investigate the interactions between GlyR α1 and α3 subtypes and 162 structurally diverse Gelsemium compounds. Physicochemical, pharmacokinetic, and toxicological analyses identified compounds with favorable bioavailability in the CNS. Molecular docking revealed that indolic alkaloids bind the GlyR orthosteric site with profiles comparable to the reference Gelsemium compound, gelsemine. Molecular dynamics simulations confirmed the stability and conformational integrity of selected ligand-receptor complexes. Overall, novel potential GlyR modulators were identified, with several compounds showing a promising selectivity profile towards GlyR α1 and α3 subtypes. These findings further support the therapeutic potential of Gelsemium alkaloids and provide a foundation for further pharmacological and toxicological validation.
Open AccessIn Silico Characterization of Gelsemium Compounds as Glycine Receptor Ligands
Glycine receptors (GlyRs) are essential for inhibitory neurotransmission in the central nervous system (CNS) and represent promising targets against neurological disorders. Several indole alkaloids from Gelsemium species have been shown to modulate GlyRs. Notably, the anxiolytic and analgesic properties of certain Gelsemium alkaloids appear to depend on GlyR modulation. However, prior studies have focused on only a few indole alkaloids, leaving the activity of other Gelsemium compound classes unexplored. This study employed an integrative in silico approach to investigate the interactions between GlyR α1 and α3 subtypes and 162 structurally diverse Gelsemium compounds. Physicochemical, pharmacokinetic, and toxicological analyses identified compounds with favorable bioavailability in the CNS. Molecular docking revealed that indolic alkaloids bind the GlyR orthosteric site with profiles comparable to the reference Gelsemium compound, gelsemine. Molecular dynamics simulations confirmed the stability and conformational integrity of selected ligand-receptor complexes. Overall, novel potential GlyR modulators were identified, with several compounds showing a promising selectivity profile towards GlyR α1 and α3 subtypes. These findings further support the therapeutic potential of Gelsemium alkaloids and provide a foundation for further pharmacological and toxicological validation.
- Open Access
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S413
INCREASES CALPAIN-1 LEVELS BY P2X2R ACTIVATION PROMOTE THE AMYLOIDOGENIC PATHWAY AND BETA-AMYLOID PEPTIDE GENERATION.
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S413
Open AccessINCREASES CALPAIN-1 LEVELS BY P2X2R ACTIVATION PROMOTE THE AMYLOIDOGENIC PATHWAY AND BETA-AMYLOID PEPTIDE GENERATION.